Correlation of altered blood albumin characteristics and lymphocyte populations to tumor stage in gastrointestinal cancer patients.

The fluorescent probe ABM was used to characterize lymphocyte membranes and blood plasma albumin from cancer patients suffering from colorectal cancer or gastric cancers at Stages II-IV. The aim of these studies was to evaluate the potential utility of measures of ABM fluorescence intensity as a standard tool in the analyses of host immune status and for a clinical interpretation of alterations in albumin per se and lymphocyte functional activity in cancer patients. The fluorescence intensity of ABM in the blood plasma decreased from control values and showed specific differences in each of the differing patients groups; these changes corresponded to cancer stage.

Altered plasma albumin characteristics and lymphocyte populations in gastrointestinal cancer patients: detection using modified fluorescence responses.

The fluorescent probe ABM (an amino derivative of benzanthrone) developed at Riga Technical University (Riga, Latvia) was used to characterize the blood plasma albumin of cancer patients (46 gastrointestinal cancer patients--30 with colorectal cancer in Stages II-IV and 16 with gastric cancer in Stage III) and of healthy controls. The fluorescence intensity of ABM in the blood plasma decreased from the control mean value and showed specific differences in the patients before (i.e.

Fluorescent probe ABM and estimation of immune state in patients with different pathologies (review article).

The fluorescent probe ABM (3-aminobenzanthrone derivative) one of the fluorescent probes synthesized in Riga Technical University proved to be an excellent, independent model for studying cell membranes. In our work we have investigated the possibility of using the fluorescent probe ABM for detection of immune state in patients with different pathologies. There is a strong correlation among all studied ABM spectral parameters, immunological characteristics, clinical and laboratory investigations of the all observed patients groups.

Fluorescent probe ABM for screening gastrointestinal patient's immune state.

The fluorescent probe-aminoderivative of benzanthrone, ABM (developed at Riga Technical University, Riga, Latvia) was used to characterize the membranes of lymphocytes of cancer patients: 46 patients with gastrointestinal diseases, 13 patients having different primary localizations with massive metastases and intoxication. Patients were divided into three groups: (1) with decreased fluorescence intensity, (2) normal fluorescence intensity, (3) increased fluorescence intensity. The lymphocytes distribution among subsets differed between groups, in correspondence to the level of fluorescence intensity.